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Background: Despite considerable research on substance-abuse placement matching, evidence is still inconclusive.
The aims of this exploratory trial are to evaluate (a) the effects of following matching guidelines on health-care
costs and heavy drinking, and (b) factors affecting the implementation of matching guidelines in the treatment of
alcohol-dependent patients.
Methods: A total of 286 alcohol-dependent patients entering one of four participating detoxification units and
having no arrangements for further treatment will be recruited. During the first week of treatment, all patients
will be administered Measurements in the Addictions for Triage and Evaluation (MATE), European Quality of
Life-Five Dimensions health status questionnaire (EQ-5D), and the Client Socio-Demographic and Service Receipt
Inventory—European Version (CSSRI-EU). Patients who are randomly allocated to the intervention group will
receive feedback regarding their assessment results, including clear recommendations for subsequent treatment.
Patients of the control group will receive treatment as usual and, if requested, global feedback regarding their
assessment results, but no recommendations for subsequent treatment. At discharge, treatment outcome and
referral decisions will be recorded. Six months after discharge, patients will be administered MATE-Outcome,
EQ-5D, and CSSRI-EU during a telephone interview.
Discussion: This trial will provide evidence on the effects and costs of using placement-matching guidelines
based on a standardized assessment with structured feedback in the treatment of alcohol-dependent patients.
A process evaluation will be conducted to facilitate better understanding of the relationship between the use
of guidelines, outcomes, and potential mediating variables.
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Patient-treatment matching in substance abuse treat-
ment (SAT) has been the subject of extensive research.
The hope has been to improve treatment outcomes by
allocating each patient to the best-fitting treatment op-
tion. Whereas attempts to match patient characteristics
with treatment modalities have so far been disappointing
[1,2], there is evidence individual patients’ needs can be
successfully matched with different treatment services
[3,4] and treatment intensities [5-7].
In order to implement patient-treatment matching in
routine care, matching guidelines have been developed
and evaluated in several countries. The guidelines usu-
ally define a set of criteria that can be used to determine
an appropriate treatment or level of care (LOC) for each
patient. In the United States, the Patient Placement
Criteria of the American Society of Addiction Medicine
are the most frequently used and evaluated placement
criteria [4,8,9]. Recently, in the Netherlands matching
guidelines were developed, evaluated, and implemented
in the context of a nationwide reorganization of the SAT
[10-12]. This approach was based on existing evidence
on the efficacy of placement matching; it combines the
concept of stepped care with the matching of treatment
services according to patients’ needs [11,12]. Depending
on their history of substance abuse treatment and their
degree of impairment along the dimensions of addiction
severity, psychiatric impairment, and social instability,
patients can be assigned to brief outpatient treatment
(LOC1), outpatient treatment (LOC2), day/residential
treatment (LOC3), or inpatient or outpatient long-term
care (LOC4; [11]). Measurements in the Addictions for
Triage and Evaluation (MATE) [13] is the assessment
instrument that was developed to implement these
guidelines. The MATE is feasible for use in routine care,
and it provides all of the information necessary to arrive
at a recommendation of one of four LOCs according to
the matching guidelines [14]. Studies on the feasibility
and predictive validity of the Dutch guidelines have
shown promising but inconclusive results. That is, the
guidelines have been implemented successfully and have
been shown to be feasible to use in routine care [11],
but there was no effect on drinking outcome at a nine-
month follow-up assessment. The authors, therefore,
recently concluded that the matching guidelines need to
be revised [15]. By now, necessary revisions are still
being discussed in the Netherlands. It should be recog-
nized, however, that various complexities are involved in
using matching guidelines and various factors affect how
effective using them is. This includes the structure of the
particular SAT service in which they are used, the num-
ber of agents involved in the decision-making process
(e.g. patients, therapists, treatment centres, funding
agencies), and regional variations in the availability oftreatment options. It is therefore appropriate to evalu-
ate matching guidelines according to the guidance for
the development and evaluation of complex interven-
tions [16].
The use of matching guidelines in the German SAT
has also been the subject of discussion [17]. Recently,
our study group conducted two pilot studies on the
feasibility of using matching guidelines for patients
with alcohol dependence following their participation
in an inpatient withdrawal program. Qualified with-
drawal treatment is a German-specific treatment pro-
gram that includes, in addition to medically supervised
detoxification, several therapeutic components aimed
at enhancing patients’ motivation to remain abstinent,
and referral for further treatment, if this is indicated
[18]. Placement-matching decisions are often made
during qualified withdrawal treatment. Our first pilot
trial that included 54 alcohol-dependent patients in
qualified withdrawal treatment indicated that both the
setting and the procedures of the study would be feas-
ible with minor adaptations [19]. In a second prepara-
tory study using Delphi methodology, we asked experts
in the German SAT to identify all relevant treatment
options for patients with alcohol-use disorders in
Germany and to organize them into four LOCs based
on current evidence and discussions among the experts
[20]. As a result, minor adaptations in the matching
guidelines were made (see Figure 1).
Methods
Trial objectives and research questions
The objectives of this study are the evaluation of the
matching approach that was previously adapted to in-
clude (a) using the MATE as the standardized intake
assessment, (b) a treatment recommendation for each
patient based on the MATE results, and (c) a feedback
session with the patient. Following the recommendations
developing and evaluating complex interventions [16],
we are combining evaluation of the efficacy of the inter-
vention with a process evaluation [21]. The hypotheses
regarding the effects of the matching guidelines on
reduction in alcohol consumption and health service
costs are as follows:
H1: Patients in the intervention group (IG) will have
fewer heavy-drinking days during the 30 days prior
to the follow-up interview than those in the control
group (CG).
H2: Patients in the IG will have lower health-service
costs during the six months after the initial assessment
than those in the CG.
The process evaluation will address the following
research questions:
R1: How are trial outcomes related to variations in
the extent and quality of the implementation of the
Figure 1 Adapted allocation guidelines for referral decisions after detoxifications.
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sites due to regional variations of the participating
SAT.
R2: What are the factors that mediate the effects of the
intervention received on treatment outcome? Mediating
variables are expected to occur at the patient level (i.e.
motivation, treatment preference, sociodemographic and
clinical characteristics), the treatment level (i.e. recom-
mendations that the therapists make, overall treatment
effects), and the regional level (i.e. regional variations in
the availability of treatment options, whether or not fund-
ing agencies approve the treatment). Previous studies
regarding placement matching imply that there may be
more variables mediating the effect of the intervention
than captured in the actual matching algorithm. Due to a
lack of evidence for major changes to the algorithm before
starting the trial, it was decided to include those variables
as possible mediators.
R3: Are there subgroups that differ in their response
to the intervention? We expect that patients having spe-
cific treatment needs, e.g. pregnant women or patients
with severe co-morbid psychiatric or physical disorders,
might differ from other patients in their response to the
intervention.Trial design and setting
The study is being conducted as a two-arm randomized
controlled trial in four German detoxification wards
offering inpatient withdrawal treatment for alcohol de-
pendence, which lasts up to three weeks. All participat-
ing detoxification wards are located in psychiatric clinics
and are specialized in withdrawal treatment for alcohol
dependence. Patients with another primary or secondary
psychiatric diagnosis are sometimes also referred to
these wards. The assessment is being given during the
first week of treatment, at treatment discharge, and six
months after discharge. In the IG, an additional assess-
ment will be given immediately after the intervention
has been completed.
Sample
The study will include patients with a primary diagnosis
of alcohol dependence who are admitted to a qualified
withdrawal program and sign an informed consent to
take part in the study. Each patient’s therapist, who is a
psychiatrist or a psychotherapist, will confirm the diag-
nosis or diagnoses at treatment entry. Exclusion criteria
include being in treatment for reasons other than alco-
hol dependence, in crisis and needing crisis intervention,
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having insufficient German language skills. Because the
aim of the study is to evaluate referral decisions, an add-
itional exclusion criterion is already having finalized
plans for referral for subsequent treatment.
Measurement
The MATE [13] is a semi-structured interview that is
based on the World Health Organisation’s biopsychoso-
cial model of health [22]. It includes 10 modules asses-
sing alcohol and drug use during the past 30 days and
the person’s lifetime, substance abuse treatment history,
psychiatric and physical co-morbidity and symptom se-
verity, diagnosis of substance -use disorder and its con-
sequences for the person’s everyday life, need for care,
and social stability. The MATE yields 20 sum scores,
which again can be summarized into four dichotomized
so called dimension scores: Addiction severity, severity
of psychiatric co-morbidity, severity of social disintegra-
tion, and history of treatment for a substance-use disorder.
With the use of these four dimensions, a recommendation
for referral to one of four LOCs can be made [13]. A
computer-assisted version of the MATE is available;
administering it takes approximately 45 minutes to
complete. The MATE-scores, including the recommenda-
tion of one of the four LOCs (LOC 1: Outpatient advice;
LOC 2: Outpatient treatment; LOC 3: Day/Residential
treatment; LOC 4: Care), are calculated automatically. The
MATE has been shown to have acceptable psychometric
properties, and it was found to be feasible for use in rou-
tine care and in research settings in both the Netherlands
and Germany [14,23].
The MATE-Outcomes is an abbreviated version of the
MATE, which was developed as a follow-up assessment
for treatment evaluation purposes.
The Client Sociodemographic and Service Receipt In-
ventory (CSSRI-EU) is a standardized Europe-wide vali-
dated instrument to evaluate health-service utilization
and medication use for the domain of mental-health care
[24]. Using the data on health service utilization, health
care costs can be estimated in a second step via monet-
ary valuation with unit costs. The CSSRI-EU can be
conducted as an interview; it takes approximately 20 mi-
nutes to complete. The validity of the German version of
the instrument [25] and cost implications based on the
CSSRI-EU have been demonstrated [26].
The European Quality of Life-Five Dimensions health
status questionnaire (EQ-5D) is a short generic quality-
of-life assessment [27] comprising EQ-5D five items:
Mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression [28]. A five-digit number is derived
that shows the person’s self-reported state of health. A
visual analogue scale (EQ VAS), ranging from (0; worst
imaginable health state) to (100; best imaginable healthstate) is also used to summarize the patient’s overall
health state. The acceptance and validity of the EQ-5D
for alcohol-dependent patients has been reported [29].
Process evaluation measures used during treatment
A structured documentation form, which we developed,
will be used to record all recommendations regarding
further treatment that are given to the patient during
withdrawal. For the patients in the IG, this includes
(a) the LOC that is recommended based on the MATE,
(b) therapists’ dissenting recommendations, if they occur,
and reasons for the disagreement, (c) results from the
feedback session, and (d) the final referral decision that
was made at discharge. For patients of the CG, referral
decisions are documented at discharge, using the same
documentation form that is used for patients in the IG. In
addition, research assistants complete a documentation
form, which includes the number of patients who are eli-
gible to participate in the study, the number of pa-
tients who agreed to participate, and for patients of
the IG the number of referral decisions that are con-
cordant with the recommendation that was derived
from the MATE.
Patients are also asked to complete a questionnaire,
which includes questions about alcohol use and psycho-
social problems [30], the patients’ preferences regarding
further treatment, and the Control Preference Scale
(CPS) [31]. With the CPS, role preferences of patients
regarding medical decision making, i.e. a passive, shared
or active role, are assessed.
Primary outcomes
The primary outcome measures will be alcohol con-
sumption and health-care costs; they will be assessed six
months after discharge from the current withdrawal
treatment. Regarding alcohol consumption, per cent
days of heavy drinking in the last 30 days (PDHD) was
chosen as the primary outcome measure [32]. It is de-
rived from the MATE-Outcomes. Health-care costs are
estimated based on data on health-service utilization as
assessed with the CSSRI-EU. The estimate includes a
monetary valuation with unit costs.
Outcomes for the process evaluation include quantita-
tive and qualitative data. In addition to the assessment
instruments and documentation forms used during the
trial, after the data have been collected, research assis-
tants and heads of the participating treatment wards will
be invited to attend a focus group to discuss potential
benefits from and barriers for an implementation of the
matching guidelines.
Intervention
After the MATE interview with patients in the IG, the
research assistant will review with the patient’s therapist
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based on the MATE results. In a subsequent feedback-
session, the research assistant will explain the recom-
mendation and will strive to reach a consensual decision
with the patient regarding further treatment. In case a
therapist has a diverging recommendation, this revised
recommendation will be explained to the patient. At the
end of the feedback session, the decision that the patient
and research assistant have made will be documented,
and the therapeutic staff will be informed about the
decision.
Patients in the CG will not have an additional feedback
session regarding their further treatment options and are
treated as usual. These patients will receive global feed-
back regarding their assessment results, without a rec-
ommendation for a LOC, if they request it.
Procedure
Immediately after admission to the withdrawal unit, pa-
tients will be invited to take part in the study. A research
assistant will inform patients about the study procedure,
and patients who wish to participate will be asked to
sign an informed consent. Patients who have done so
will be asked to complete a questionnaire prior to their
first assessment. This assessment will be scheduled when
a patient’s withdrawal symptoms have decreased to a
minimal level as judged by the medical staff. During the
assessment interview, a research assistant will administer
the MATE, CSSRI-EU, and EQ-5D. Finally, the research
assistant will be informed by the computer-assisted
MATE, whether the patient has been randomly assigned
to either the IG or the CG. For patients in the IG, the
research assistant will schedule the feedback session.Figure 2 Flowchart of patient progress through the qualified withdra
Addictions for Triage and Evaluation; CSSRI = Client Sociodemograph
questionnaire; IG = Intervention group; CG = Control group.At the end of the withdrawal treatment, all decisions
and arrangements regarding subsequent treatment will
be documented for patients in both the IG and the CG.
Six months after discharge from the withdrawal treat-
ment, patients are contacted for a telephone follow-up
interview, which will include the MATE-Outcomes,
CSSRI-EU, and EQ-5D. Patients who complete the entire
procedure including the follow-up assessment will re-
ceive payment of 30 euros. The study procedure is dia-
grammed in Figure 2.
Randomization
Randomization occurs by means of computerized
blocked randomization with varying block sizes that are
stratified by trial site. Research assistants are blinded
until the first assessment has been completed.
Sample-size calculation
Due to the exploratory nature of the trial, the sample-
size calculation was based on considerations regarding
the process evaluation rather than the primary outcome
measures. The concordance between MATE recommen-
dations and actual referrals to the recommended LOC
was considered to be an important mediator between
the intervention and the outcome measures. Because
classification into concordant (matched) and discordant
(mismatched) decisions yields a cross-classification in
addition to the LOC groups and study arms, it was im-
portant to ensure that in both study arms all of the cells
include at least 10 analyzable cases at the six-month
follow-up. Based on prior studies [11,19], we expected
an imbalance between the four LOCs (approximate ratio:
1:3:5:1). Based on these assumptions, 100 analyzablewal unit and study procedure; MATE =Measurements in the
ic and Service Receipt Inventory; EQ5D = EQ-5D Health
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ing a drop-out rate of 30 % between randomization and
follow-up, 143 patients should initially be included in
each study arm (or 286 patients in total). This sample
size would ensure that subgroup analyses can be con-
ducted, even if attrition rates are higher than expected
or they differ among study arms or LOCs. Figure 3
shows the expected flow of patients.
Statistical analyses
All of the primary analyses will be conducted according
to the intention-to-treat principle (ITT). There is a risk
that not every patient in the IG will have a feedback ses-
sion during his or her withdrawal treatment. This could
result from time constraints for the therapists, unsched-
uled dropouts from treatment, or premature referrals for
subsequent treatment. Therefore, additional per-protocol
analyses will be conducted that include only those patients
who actually participated in the intervention. In order to
evaluate the robustness of the results, missing data will be
addressed by using at least two procedures (e.g. complete
case analyses, imputation by expectation-maximization,
multiple imputation by chained equations), depending on
the outcome and the patterns in the missing data. Differ-
ences between the two treatment arms regarding the pri-
mary outcomes will be analyzed using generalized linearFigure 3 Approximated patient flow of MATE-LOC.models with gamma distribution and log-link function
controlling for confounders (e.g. baseline costs and
PDHD, age, gender, co-morbidity, EQ-5D scores). To ac-
count for correlated patient data caused by the multicen-
ter structure, random-effect models will be applied.
Subgroup analyses will include effects of the classifica-
tion as matched vs. mismatched decisions for patients in
both the IG and the CG. That is, patients who received
treatment according to MATE guidelines will be desig-
nated matched, and those who did not will be designated
as mismatched. The effect of matching MATE recom-
mendations with treatment received on the primary out-
come measures will be analyzed using multiple linear
regressions. Therapists’ documented reasons for decid-
ing to deviate from MATE-LOC recommendations will
also be analyzed in order to decide whether the decision
algorithm should be modified. Additional exploratory
analyses will be conducted to determine the relevance
that patients’ demographic and clinical characteristics,
their motivation for treatment, and their treatment pref-
erences has for patient-treatment matching.
Data monitoring and quality assurance
Research assistants will receive two days of training in
the study procedures, data monitoring, how to adminis-
ter the assessments, and how to conduct the feedback
Buchholz et al. BMC Psychiatry 2014, 14:286 Page 7 of 9
http://www.biomedcentral.com/1471-244X/14/286sessions. All assessment interviews and feedback ses-
sions will be audiotaped. The coordinator of the study
will supervise every fifth interview and feedback session
to ensure that the research assistants adhere to the
intended protocol. Data monitoring will be under the
auspices of the Institut fuer Therapieforschung (IFT).
Each study center will send all of the assessments con-
ducted during the withdrawal treatment to the IFT. In
turn, a research assistant at the IFT will continuously re-
view the data sets and will report missing or incomplete
data to the study center. If possible, research assistants
complete missing data and then report back to the IFT.
Confidentiality and ethical approval
Both the ethics committee of the local medical associ-
ation in Hamburg, the Ethik-Kommission der Ärztekam-
mer Hamburg (Reference Number PV4325) and the
ethics committee at each of the participating sites have
approved the study protocol, including all of the patient
information that will be collected, and the informed
consent documents that patients will be asked to sign.
Ethical approval was granted in accordance with the
principles of the Declaration of Helsinki [33]. Patients’
participation in the study will be voluntary, and confi-
dentiality will be assured. Because participants’ names
and telephone numbers will be needed in order to con-
tact them for the follow-up interview, the data cannot be
stored anonymously until after the follow-up assess-
ments have been completed. Prior to this, pseudonyms
will be used, and personal data will be stored separately.
When the follow-up assessments have been completed,
the personal data will be deleted.
Discussion
Based on a randomized controlled design, the current
study will empirically evaluate a matching procedure
that includes a standardized assessment, a recommenda-
tion derived from the assessment results, and a feedback
session. Thus, the study will advance the work of Dutch
colleagues who designed the MATE and the MATE
matching algorithm and conducted large-scale naturalis-
tic trials involving the entire Dutch SAT [10-12,14,15].
In the current study, we have the opportunity to (a) use
a randomized controlled design, and to (b) evaluate the
matching approach in a different health-care system.
There are, however, several potential threats to consider
in conduct of the study and in analyzing and interpret-
ing the results.
First, the proposed intervention combines several steps:
Evaluation of each patient’s eligibility for the matching
process; a LOC recommendation based on the patient’s
MATE, results; and the therapist’s possible modified
recommendation, which would be explained to the patient
during a feedback session. At this time, we cannotestimate how often the therapists will deviate from the
original LOC recommendation. Another important factor
that can affect referral decisions is whether or not insur-
ance agencies (i.e. health insurance, pension funds, or
social welfare) approve and finance the treatment that is
recommended. As part of our follow-up assessment, we
will record whether patients applied for a treatment that
was not approved. We can, therefore, estimate the
frequency with which applications are not approved and
take this into consideration when making the LOC recom-
mendations in the process-evaluation phase of the trial.
In this trial, we are focusing on the time period imme-
diately after the withdrawal treatment and up to six
months after treatment. This time period might be too
short to reliably estimate differences between the groups
in health-care costs and alcohol use. This follow-up
interval, however, was chosen for practical reasons.
Moreover, it will allow us to closely monitor actual refer-
rals following withdrawal and determine how they are
related to the LOC that was recommended. If this
approach succeeds in allocating patients completing the
withdrawal treatment to appropriate subsequent treat-
ment, a larger trial will be needed to derive a more valid
and reliable estimation of the effects.
The treatment as usual during qualified withdrawal
treatment may have an impact on the ability of the study
design to detect group differences. Since one part of the
treatment includes discussions regarding further treat-
ment, differences between IG and CG may be decreased.
However, the choice of the treatment setting for this
study has been made for several reasons and has been
piloted in a previous study (19). In contrast to the Dutch
studies, this study will include only one part of the
German SAT, i.e. qualified withdrawal treatment for
patients with alcohol dependence. Matching processes
do, however, occur in several other parts of the German
SAT (e. g. drug counselling services) and in primary
care. Additionally, systematic integration of decisions to
refer patients with co-morbid disorders other than sub-
stance use to psychiatric treatment or social care might
need to be made. By including a process evaluation, we
expect to obtain initial answers that can serve as the
basis for further discussion. How to evaluate the gen-
eralizability of this approach for other parts of the
German SAT will be a major issue in the discussion and
interpretation of the results. In order to achieve a broad
and successful implementation of the matching guide-
lines, much political and scientific discussion will be
needed, and it will be necessary to integrate them with
existing national treatment guidelines.
Trial registration and status
This study is registered with the German Clinical Trials
Register as Trial DRKS00005035. Date of registration:
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http://www.biomedcentral.com/1471-244X/14/28603/06/2013. Recruitment of participants started in June
2013, and testing participants, including the follow-up
assessments, is expected to be completed in December
2014. This is the first draft of the study protocol, there
have been no amendments or changes made in the trial
design. Date of first submission: 28.04.2014. Date of sec-
ond submission: 3.09.2014.
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